L-Alanine
Also known as: Alanine, L-Alanine free form, Beta-alanine precursor
This ingredient is classified as unclassified risk.
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
L-Alanine is a non-essential amino acid involved in glucose metabolism and muscle energy production. It is safe at standard supplemental doses. It may mildly affect blood glucose levels; caution in diabetic patients at very high doses. No significant drug interactions documented.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Amino Acids
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for L-Alanine indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 ივნ 2026, 12:03
Evidence Distribution
-
Observational / other LOW evidence YELLOWAssociations of Fasting Glucagon and the Glucagon-Alanine Index With Hepatic Steatosis and Liver Stiffness in Japanese Individuals With Type 2 Diabetes. ↗Hattori T et al.. Associations of Fasting Glucagon and the Glucagon-Alanine Index With Hepatic Steatosis and Liver Stiffness in Japanese Individuals With Type 2 Diabetes.. Diabetes Obes Metab. 2026. PMID:42244477.PMID 42244477 ↗Journal Diabetes Obes MetabYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42244477/
-
Observational / other LOW evidence YELLOWAla-Ce@Ce6 hybrid supramolecular nanozyme for oxygen self-supplying hypoxia photodynamic therapy. ↗Li C et al.. Ala-Ce@Ce6 hybrid supramolecular nanozyme for oxygen self-supplying hypoxia photodynamic therapy.. Biomaterials. 2026. PMID:42229300.PMID 42229300 ↗Journal BiomaterialsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42229300/
-
Observational / other LOW evidence YELLOWAtypical Thyroid Storm Manifesting as Refractory Hypoglycemia and Fulminant Liver Failure in an Older Woman: A Case Report. ↗Jiang YZ et al.. Atypical Thyroid Storm Manifesting as Refractory Hypoglycemia and Fulminant Liver Failure in an Older Woman: A Case Report.. Am J Case Rep. 2026. PMID:42226431.PMID 42226431 ↗Journal Am J Case RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42226431/
-
Observational / other LOW evidence YELLOWAnaerobic metabolic evolution for homotypic L-valine fermentation. ↗Yang S et al.. Anaerobic metabolic evolution for homotypic L-valine fermentation.. Nat Commun. 2026. PMID:42215457.PMID 42215457 ↗Journal Nat CommunYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42215457/
-
Observational / other LOW evidence YELLOWImpact of cannabis, benzodiazepines, and methamphetamine use on inflammatory and hepatic biomarkers in Benin City, Nigeria: a case-control study. ↗Usman-Onoruvie VO et al.. Impact of cannabis, benzodiazepines, and methamphetamine use on inflammatory and hepatic biomarkers in Benin City, Nigeria: a case-control study.. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID:42183857.PMID 42183857 ↗Journal Naunyn Schmiedebergs Arch PharmacolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42183857/
-
Observational / other LOW evidence YELLOWSevere Dengue-Associated Hepatitis in an Adolescent Treated With Oral Acetylcysteine: A Case Report. ↗Morales Reyes AO et al.. Severe Dengue-Associated Hepatitis in an Adolescent Treated With Oral Acetylcysteine: A Case Report.. Cureus. 2026. PMID:42182546.PMID 42182546 ↗Journal CureusYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42182546/
-
Observational / other LOW evidence YELLOWA Stereospecific Lactic Acid Exclusion Biosensor for Grass Silage Fed Green Biorefinery. ↗van Roosmalen RN et al.. A Stereospecific Lactic Acid Exclusion Biosensor for Grass Silage Fed Green Biorefinery.. Microb Biotechnol. 2026. PMID:42169395.PMID 42169395 ↗Journal Microb BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42169395/
-
Observational / other LOW evidence YELLOWNon-targeted metabolomics reveals myocardial metabolic alterations in epileptic rats. ↗Hu Y et al.. Non-targeted metabolomics reveals myocardial metabolic alterations in epileptic rats.. PLoS One. 2026. PMID:42166425.PMID 42166425 ↗Journal PLoS OneYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42166425/
-
Observational / other LOW evidence YELLOWu03b1-L-Tyrosine under high pressure: validation of phase transitions and a curious similarity with L-alanine. ↗Sharaya SS et al.. u03b1-L-Tyrosine under high pressure: validation of phase transitions and a curious similarity with L-alanine.. Acta Crystallogr B Struct Sci Cryst Eng Mater. 2026. PMID:42148599.PMID 42148599 ↗Journal Acta Crystallogr B Struct Sci Cryst Eng MaterYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42148599/
-
Observational / other LOW evidence YELLOWThe lytic transglycosylase MltA participates in turnover of septal peptidoglycan in Escherichia coli. ↗Yahashiri A et al.. The lytic transglycosylase MltA participates in turnover of septal peptidoglycan in Escherichia coli.. bioRxiv. 2026. PMID:42146403.PMID 42146403 ↗Journal bioRxivYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42146403/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for L-Alanine. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for L-Alanine
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.